Australia's CSL Slapped With U.S. FDA Warning Letter Over Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA's Center for Biologics Evaluation and Research slapped CSL Biotherapies with a warning letter June 15 for significant objectionable conditions related to current good manufacturing practices at its Victoria, Australia, manufacturing plant
You may also be interested in...
Pediatric Weight Gain From Atypical Antipsychotics Returns To FDA Advisory Cmte.
Panel urged label changes two years ago, but the products still do not include uniform information in their warning sections. FDA is asking its Pediatric Advisory Committee to review the pediatric safety of Bristol/Otsuka's Abilify, along with an AHRQ report on weight gain associated with the class of products.
Pediatric Weight Gain From Atypical Antipsychotics Returns To FDA Advisory Cmte.
Panel urged label changes two years ago, but the products still do not include uniform information in their warning sections. FDA is asking its Pediatric Advisory Committee to review the pediatric safety of Bristol/Otsuka's Abilify, along with an AHRQ report on weight gain associated with the class of products.
Flu Vaccine Demand Forecast: Flat Or Up Slightly Compared With Last Year
The five providers of the six approved seasonal influenza vaccines appear to be preparing for a similar season with similar sales in 2011-12 as they had last year.